Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18990552 | 0.93 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL10507710 | 0.93 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL31647529 | 0.90 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL1865158 | 0.89 | CA1 (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14453897 | 0.89 | CA1 (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL24305309 | 0.88 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL10076979 | 0.86 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL7866645 | 0.86 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14453900 | 0.85 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL8814209 | 0.83 | CA1 (0.45) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077988-A1 | BRANCHED HETERO POLYETHYLENE GLYCOL AND INTERMEDIATE | NOF CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077988-A1 | BRANCHED HETERO POLYETHYLENE GLYCOL AND INTERMEDIATE | F12, FGB, F13B | CA1 1057/4885CA2 2103/4885CA7 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.